Artemisinin Resistance In Malaria Treated With IV Artesunate
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The spread of artemisinin resistant falciparum malaria presents new challenges to both the
control and treatment of malaria. Loss of ring stage susceptibility to the artemisinins might
jeopardize the use of parenteral artesunate as the first line drug for the treatment of
severe falciparum malaria.
The purpose of this study is to assess the effect of artemisinin resistance (defined by a
Kelch13 mutation with known functional significance) in P. falciparum malaria requiring
parenteral artesunate treatment on lactate clearance parameters.
Details
Lead Sponsor:
University of Oxford
Collaborators:
Mahidol Oxford Tropical Medicine Research Unit Oxford University Clinical Research Unit, Vietnam